ICCC IMMUCELL CORP revenue, earnings and financials
For the quarter ended June 30, 2026, IMMUCELL CORP reported revenue of $7.19M (up 11.5% from a year earlier), net income of $1.83M and diluted EPS of $0.20; over the last four quarters revenue was $30.7M and net income $787K; for the fiscal year ended December 2025 revenue was $27.6M, up 4.3% on the year before.
ICCC annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $27.6M, gross profit $11.4M, operating income $1.65M, net income −$1.04M (margin -3.8%), EPS −$0.12
- Fiscal year ended Dec 2024: revenue $26.5M, gross profit $7.94M, operating income −$1.64M, net income −$2.16M (margin -8.1%), EPS −$0.26
- Fiscal year ended Dec 2023: revenue $17.5M, gross profit $3.87M, operating income −$5.75M, net income −$5.78M (margin -33.1%), EPS −$0.75
- Fiscal year ended Dec 2022: revenue $18.6M, gross profit $7.65M, operating income −$2.30M, net income −$2.49M (margin -13.4%), EPS −$0.32
- Fiscal year ended Dec 2021: revenue $19.2M, gross profit $8.66M, operating income $257K, net income −$78.3K (margin -0.4%), EPS −$0.01
ICCC quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $7.19M (up 11.5% year over year), net income $1.83M, EPS $0.20
- Quarter ended Mar 31, 2026: revenue $10.4M (up 28.4% year over year), net income $1.94M, EPS $0.21
- Quarter ended Dec 31, 2025 (from the annual report): revenue $7.63M (down 1.6% year over year), net income −$2.85M, EPS −$0.32
- Quarter ended Sep 30, 2025: revenue $5.51M (down 8.4% year over year), net income −$140K, EPS −$0.02
- Quarter ended Jun 30, 2025: revenue $6.44M (up 17.8% year over year), net income $502K, EPS $0.06
- Quarter ended Mar 31, 2025: revenue $8.07M (up 11.2% year over year), net income $1.45M, EPS $0.16
- Quarter ended Dec 31, 2024 (from the annual report): revenue $7.75M (up 52.1% year over year), net income $514K, EPS $0.09
- Quarter ended Sep 30, 2024: revenue $6.01M (up 11.4% year over year), net income −$702K, EPS −$0.09
- Quarter ended Jun 30, 2024: revenue $5.47M (up 54.9% year over year), net income −$1.53M, EPS −$0.20
- Quarter ended Mar 31, 2024: revenue $7.26M (up 110.6% year over year), net income −$438K, EPS −$0.06
- Quarter ended Dec 31, 2023 (from the annual report): revenue $5.10M (up 30.3% year over year), net income −$1.14M, EPS −$0.15
- Quarter ended Sep 30, 2023: revenue $5.40M (up 12.5% year over year), net income −$940K, EPS −$0.12
- Quarter ended Jun 30, 2023: revenue $3.53M (down 8.5% year over year), net income −$1.38M, EPS −$0.18
- Quarter ended Mar 31, 2023: revenue $3.45M (down 42.6% year over year), net income −$2.32M, EPS −$0.30
- Quarter ended Dec 31, 2022 (from the annual report): revenue $3.91M (down 28.2% year over year), net income −$1.67M, EPS −$0.22
- Quarter ended Sep 30, 2022: revenue $4.80M (down 6.9% year over year), net income −$655K, EPS −$0.08
- Quarter ended Jun 30, 2022: revenue $3.86M (down 15.0% year over year), net income −$684K, EPS −$0.09
- Quarter ended Mar 31, 2022: revenue $6.00M (up 46.1% year over year), net income $513K, EPS $0.07
- Quarter ended Dec 31, 2021 (from the annual report): revenue $5.44M, net income $74.1K, EPS $0.01
- Quarter ended Sep 30, 2021: revenue $5.15M, net income $148K, EPS $0.02
ICCC cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $2.48M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $358K, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$4.67M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$1.54M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow $954K, share buybacks n/a
ICCC balance sheet
- Jun 30, 2026: cash $8.86M, total assets $46.6M, total liabilities $15.3M, shareholders' equity $31.4M, long-term debt $6.80M
- Mar 31, 2026: cash $6.81M, total assets $44.1M, total liabilities $15.0M, shareholders' equity $29.1M, long-term debt $7.07M
- Dec 31, 2025: cash $3.81M, total assets $42.5M, total liabilities $15.5M, shareholders' equity $27.1M, long-term debt $7.49M
- Sep 30, 2025: cash $3.89M, total assets $45.7M, total liabilities $15.9M, shareholders' equity $29.8M, long-term debt $7.90M
- Jun 30, 2025: cash n/a, total assets $42.5M, total liabilities $16.9M, shareholders' equity $29.9M, long-term debt $8.26M
- Mar 31, 2025: cash n/a, total assets $45.6M, total liabilities $16.6M, shareholders' equity $29.0M
- Dec 31, 2024: cash $3.76M, total assets $45.1M, total liabilities $17.6M, shareholders' equity $27.5M, long-term debt $9.04M
- Sep 30, 2024: cash n/a, total assets $44.4M, total liabilities $18.0M, shareholders' equity $26.4M
What is ICCC's revenue?
IMMUCELL CORP reported $30.7M of revenue over its last four quarters, through June 30, 2026.
Is ICCC profitable?
Yes. IMMUCELL CORP earned $787K over the last four quarters.
What is ICCC's EPS?
Diluted earnings per share over the last four quarters were $0.07; $0.20 in the latest quarter.